Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

How can we tell whether EGFR inhibitors effectively inhibit the key pathways driving EGFR-mediated radioresistance? Considering tumor instability and heterogeneity, how can we optimize the ...

dysregulation in the EGFR pathway is implicated in various cancers. In order to test whether antibodies are specific to EGFR or to any of its downstream targets, researchers can knock out critical ...

Signal transduction pathways implicated in radiosensitization by EGFR inhibitors. Tyrosine phosphorylation on key intracellular residues of EGFR recruits docking proteins, including the SH2 domain ...